Becton, Dickinson and Company (NYSE:BDX) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) issued its earnings results on Thursday. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.13, FiscalAI reports. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. During the same quarter last year, the business posted $3.35 EPS. The company's revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company updated its FY 2026 guidance to 12.520-12.720 EPS.

Here are the key takeaways from Becton, Dickinson and Company's conference call:

• BD beat Q2 expectations with $4.7 billion revenue (+2.6%), adjusted operating margin of 24.2% and adjusted EPS of $2.90, and raised full‑year adjusted EPS guidance to $12.52–$12.72 while reaffirming low‑single‑digit revenue growth.
• Strategic growth platforms scaled — double‑digit growth in biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration, with biologics now ~55% of Biopharma Systems revenue.
• BD Excellence drove operational leverage, delivering ~8% productivity in the quarter, >90% service levels, a $150M run‑rate toward the $200M cost‑out goal, and a simplified manufacturing footprint (~50 sites) to support margin expansion and cash flow.
• FDA warning letter for the El Paso facility led BD to place ChloraPrep/PurePrep U.S. shipments on temporary hold for additional testing (expected ~3 weeks); manufacturing continues and no patient safety signals reported.
• Capital allocation emphasized shareholder returns — $2.3 billion returned this quarter (including $2.0B share repurchases), $1.1B YTD free cash flow, and continued focus on disciplined tuck‑in M&A while targeting long‑term net leverage ~2.5x (currently ~2.9x).

Becton, Dickinson and Company Trading Down 4.2%

Shares of BDX stock opened at $143.11 on Tuesday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The company has a market cap of $39.43 billion, a PE ratio of 36.23, a price-to-earnings-growth ratio of 10.60 and a beta of 0.22. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The business's 50 day moving average is $157.19 and its two-hundred day moving average is $180.46.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company's dividend payout ratio is 106.33%.

Analyst Ratings Changes

BDX has been the subject of a number of research reports. Barclays lifted their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an "overweight" rating in a research report on Monday. Stifel Nicolaus cut their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Evercore lifted their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Citigroup lowered their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a "buy" rating for the company in a research note on Tuesday, February 10th. Finally, TD Cowen cut their price objective on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a "hold" rating on the stock in a research report on Monday, May 4th. Seven research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $184.86.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share repurchase program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's leadership believes its shares are undervalued.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 953 shares of the company's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares of the company's stock, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 1,102 shares of company stock valued at $198,909 in the last ninety days. 0.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares during the period. Empowered Funds LLC grew its holdings in Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier's stock valued at $1,827,000 after buying an additional 1,354 shares during the last quarter. United Bank increased its position in Becton, Dickinson and Company by 23.9% in the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier's stock worth $887,000 after buying an additional 993 shares during the period. Marshall Wace LLP lifted its holdings in shares of Becton, Dickinson and Company by 365.1% during the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier's stock worth $5,491,000 after buying an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 34.7% in the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier's stock valued at $4,048,000 after acquiring an additional 6,058 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.